Samsung Biologics union continues strike regarding wages, other issues

Unionized workers at Samsung Biologics, the biotech arm of Samsung, continued their strike on Saturday, according to union officials, with the union and the company showing little sign of bridging gaps regarding wages and other issues.

2026-05-02

Samsung Biologics union launches 1st general strike over pay dispute

Unionized workers at Samsung Biologics, the biotech arm of Samsung Group, began a five-day general strike on Friday, demanding higher wages and expanded performance-based compensation.

2026-05-01

Samsung Biologics union declares intent to strike after court partially dismisses injunction request

The labor union of Samsung Biologics will proceed with a five-day strike starting Friday after a court only partially approved the company's request for an injunction.

2026-04-28

Samsung Biologics finalizes acquisition of GSK's Maryland plant

Samsung Biologics finalized the acquisition of GSK's biopharmaceutical manufacturing facility in Rockville, Maryland, securing its first production base in the United States.

2026-04-01

Samsung Biologics signs $189 million drug manufacturing contract with European partner

Samsung Biologics said Friday that it signed a contract worth $188.95 million with a European pharmaceutical company to manufacture drugs under a contract manufacturing organization agreement.

2026-03-13

Samsung Biologics breaks profit records as it expands production capacity

Samsung Biologics posted a record annual operating profit of more than 2 trillion won ($1.4 billion) in 2025, driven by expanded production capacity and a weaker won, the company said on Wednesday.

2026-01-21

Samsung Biologics to launch ADC drug product service in 2027

Samsung Biologics is preparing to launch an antibody-drug conjugate (ADC) drug product service in the first quarter of 2027, reflecting its efforts to more closely link drug development with downstream manufacturing.

2026-01-18

Lotte Biologics, Rakuten Medical sign deal on producing new cancer treatment drug

Lotte Biologics signed a contract manufacturing organization (CMO) agreement with Rakuten Medical on Tuesday to produce and commercialize Rakuten’s photoimmunotherapy (PIT) drug, an antibody-dye conjugate used in the treatment of cancer.

2026-01-14

Samsung Biologics looks to scale up U.S. manufacturing in Maryland

Samsung Biologics is seeking to strengthen its U.S. footprint by expanding capacity at its recently acquired manufacturing facility in Rockville, Maryland, as it seeks to meet growing customer demand for U.S.-based production.